The blog has highlighted a number of stories concerning the detrimental influence of the pharmaceutical industry on the progress in finding a vaccine to tackle the COVID-19 pandemic.
The Times, too, has focused on the topic with a 3rd August 2020 article, explaining the drug-manufacturers policy of pricing.
Overall, according to a healthcare banking informant it would be " a complete PR disaster for any big pharma company to price a vaccine at a significant profit."
The media message being issued is that the initial vaccine will be sold to governments at above cost to recoup research and development expenses but the profits accrued will be modest.
Nevertheless, much of their business model is based upon the current flu shots. A future lucrative commercial market opportunity will avail itself with annual re-vaccinations.
The Times, too, has focused on the topic with a 3rd August 2020 article, explaining the drug-manufacturers policy of pricing.
Overall, according to a healthcare banking informant it would be " a complete PR disaster for any big pharma company to price a vaccine at a significant profit."
The media message being issued is that the initial vaccine will be sold to governments at above cost to recoup research and development expenses but the profits accrued will be modest.
Nevertheless, much of their business model is based upon the current flu shots. A future lucrative commercial market opportunity will avail itself with annual re-vaccinations.
No comments:
Post a Comment